Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pharma-Bio ServPBSV -11.11%45 EV-to-EBIT is 4.20 as of Sep. 17, 2026, which is 59% above its 10-year median of 2.64. GuruFocus rates PBSV with a GF Score™ of 45/100 and a GF Value™ of $0.61 (Possible Value Trap). The stock has 2 warning signs investors should review. Among 481 Healthcare Providers & Services companies, Pharma-Bio Serv ranks better than 96.47% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Pharma-Bio Serv's Enterprise Value for the quarter that ended in Apr. 2026 was $2.98 Mil.
Pharma-Bio Serv's EBIT for the trailing twelve months (TTM) ended in Apr. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.40 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pharma-Bio Serv EV-to-EBIT Related Terms
Pharma-Bio Serv EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Pharma-Bio Serv's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Health Information Services subindustry, Pharma-Bio Serv's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pharma-Bio Serv EV-to-EBIT vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Pharma-Bio Serv's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Pharma-Bio Serv's EV-to-EBIT falls into.
Pharma-Bio Serv's current Enterprise Value is $-1.67 Mil.
Pharma-Bio Serv's EBIT for the trailing twelve months (TTM) ended in Apr. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.40 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pharma-Bio Serv (PBSV) has a EV-to-EBIT of 4.20 as of Sep. 17, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Pharma-Bio Serv and its competitors. This is 59% above median its historical median of 2.64. According to the industry distribution chart, Pharma-Bio Serv ranks #17 out of 481 companies in the Healthcare Providers & Services industry, placing it in the top 3.5%.
Is Pharma-Bio Serv's EV-to-EBIT too high?
Pharma-Bio Serv's current EV-to-EBIT of 4.20 is 59% above median its 10-year median of 2.64. The Healthcare Providers & Services industry median EV-to-EBIT is 14.78. Pharma-Bio Serv's value of 4.20 is 71.6% below this industry median. Based on the distribution chart, Pharma-Bio Serv ranks #17 out of 481 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Pharma-Bio Serv has a GF Score™ of 45/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Pharma-Bio Serv's EV-to-EBIT compare to HCTI and BFRG?
According to the Healthcare Providers & Services industry distribution chart, Pharma-Bio Serv ranks #17 out of 481 companies for EV-to-EBIT. This places Pharma-Bio Serv in the top 4% of its industry — outperforming the majority of peers. The industry median EV-to-EBIT is 14.78. Pharma-Bio Serv's value of 4.20 is 71.6% below this benchmark. While the company's 10-year median is 2.64 vs. the industry median of 14.78, Pharma-Bio Serv has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Healthcare Providers & Services company?
The median EV-to-EBIT among Healthcare Providers & Services companies is 14.78, based on 481 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pharma-Bio Serv's current EV-to-EBIT of 4.20 is 71.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Pharma-Bio Serv and its competitors. For the Healthcare Providers & Services industry, the median EV-to-EBIT is 14.78 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pharma-Bio Serv's current EV-to-EBIT is 4.20, which is 59% above median its own 10-year median of 2.64. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharma-Bio Serv stock overvalued right now?
Based on GuruFocus' analysis, Pharma-Bio Serv (PBSV) is currently considered Possible Value Trap. The stock's GF Value™ is $0.61, compared to a current price of $0.40 — trading 34.4% below its estimated fair value. The current EV-to-EBIT is 4.20, which is 59% above median its 10-year median of 2.64 and 71.6% below the Healthcare Providers & Services industry median of 14.78. Pharma-Bio Serv's overall GF Score™ is 45/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Pharma-Bio Serv (PBSV), the current EV-to-EBIT is 4.20 as of Sep. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pharma-Bio Serv (PBSV) Overvalued in 2026?
Based on GuruFocus' analysis, Pharma-Bio Serv stock appears to be undervalued.
The current stock price of $0.40 is trading 34.4% below its estimated GF Value™ of $0.61.
GuruFocus considers Pharma-Bio Serv to be Possible Value Trap.
Key valuation signals for PBSV:
EV-to-EBIT: 4.20 (59% above median its 10-year median of 2.64)
GF Value™: $0.61 vs. price of $0.40 (34.4% below fair value)
Industry Position: 71.6% below the Healthcare Providers & Services median (#17 of 481)
No single metric tells the full story. See the PBSV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pharma-Bio Serv Inc is a compliance and technology transfer services consulting firm. It also provides microbiological testing services and chemical testing services through its laboratory testing facility in Puerto Rico. It has three reportable segments: Puerto Rico technical compliance consulting which is the key revenue driver; United States technical compliance consulting; and Europe technical compliance consulting. The company offers solutions to the pharmaceutical, chemical, biotechnology, medical devices, cosmetic and food industries, and allied products companies. It generates maximum revenue from Puerto Rico and also has its presence in United States, Europe and Other countries.
45GF Score
Get the complete analysis for PBSV
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PBSV has been successfully added to your 
